Literature DB >> 31046065

Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer.

Bram De Laere1,2, Prabhakar Rajan3, Henrik Grönberg1, Luc Dirix2,4, Johan Lindberg5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31046065      PMCID： PMC6499126          DOI： 10.1001/jamaoncol.2019.0869

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  6 in total

1.  Nuclear Circulating Tumor Cell Androgen Receptor Variant 7 in Castration-Resistant Prostate Cancer: The Devil Is in the Detail.

Authors:  Stephen R Plymate; Adam Sharp; Johann S de Bono
Journal:  JAMA Oncol       Date:  2018-09-01       Impact factor: 31.777

2.  Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.

Authors:  Matti Annala; Gillian Vandekerkhove; Daniel Khalaf; Sinja Taavitsainen; Kevin Beja; Evan W Warner; Katherine Sunderland; Christian Kollmannsberger; Bernhard J Eigl; Daygen Finch; Conrad D Oja; Joanna Vergidis; Muhammad Zulfiqar; Arun A Azad; Matti Nykter; Martin E Gleave; Alexander W Wyatt; Kim N Chi
Journal:  Cancer Discov       Date:  2018-01-24       Impact factor: 39.397

3.  Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns.

Authors:  Bram De Laere; Pieter-Jan van Dam; Tom Whitington; Markus Mayrhofer; Emanuela Henao Diaz; Gert Van den Eynden; Jean Vandebroek; Jurgen Del-Favero; Steven Van Laere; Luc Dirix; Henrik Grönberg; Johan Lindberg
Journal:  Eur Urol       Date:  2017-01-16       Impact factor: 20.096

4.  Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide.

Authors:  Emmanuel S Antonarakis; Changxue Lu; Brandon Luber; Hao Wang; Yan Chen; Yezi Zhu; John L Silberstein; Maritza N Taylor; Benjamin L Maughan; Samuel R Denmeade; Kenneth J Pienta; Channing J Paller; Michael A Carducci; Mario A Eisenberger; Jun Luo
Journal:  J Clin Oncol       Date:  2017-04-06       Impact factor: 44.544

5.  TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer.

Authors:  Bram De Laere; Steffi Oeyen; Markus Mayrhofer; Tom Whitington; Pieter-Jan van Dam; Peter Van Oyen; Christophe Ghysel; Jozef Ampe; Piet Ost; Wim Demey; Lucien Hoekx; Dirk Schrijvers; Barbara Brouwers; Willem Lybaert; Els G Everaert; Daan De Maeseneer; Michiel Strijbos; Alain Bols; Karen Fransis; Nick Beije; Inge E de Kruijff; Valerie van Dam; Anja Brouwer; Dirk Goossens; Lien Heyrman; Gert G Van den Eynden; Annemie Rutten; Jurgen Del Favero; Mattias Rantalainen; Prabhakar Rajan; Stefan Sleijfer; Anders Ullén; Jeffrey Yachnin; Henrik Grönberg; Steven J Van Laere; Johan Lindberg; Luc Y Dirix
Journal:  Clin Cancer Res       Date:  2018-09-12       Impact factor: 12.531

6.  Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.

Authors:  V Conteduca; D Wetterskog; M T A Sharabiani; E Grande; M P Fernandez-Perez; A Jayaram; S Salvi; D Castellano; A Romanel; C Lolli; V Casadio; G Gurioli; D Amadori; A Font; S Vazquez-Estevez; A González Del Alba; B Mellado; O Fernandez-Calvo; M J Méndez-Vidal; M A Climent; I Duran; E Gallardo; A Rodriguez; C Santander; M I Sáez; J Puente; D Gasi Tandefelt; A Wingate; D Dearnaley; F Demichelis; U De Giorgi; E Gonzalez-Billalabeitia; G Attard
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976
  6 in total
  8 in total

1.  Circulating tumor DNA genomic profiling reveals the complicated olaparib-resistance mechanism in prostate cancer salvage therapy: A case report.

Authors:  Fang Yuan; Nan Liu; Ming-Zhen Yang; Xiao-Tian Zhang; Hong Luo; Hong Zhou
Journal:  World J Clin Cases       Date:  2022-04-16       Impact factor: 1.534

2.  Androgen receptor variant-driven prostate cancer II: advances in clinical investigation.

Authors:  Emmanuel S Antonarakis; Jun Luo; Andrew J Armstrong; Landon C Brown; Changxue Lu
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-02-24       Impact factor: 5.554

3.  Novel PGK1 determines SKP2-dependent AR stability and reprograms granular cell glucose metabolism facilitating ovulation dysfunction.

Authors:  Xia Liu; Changfa Sun; Kexin Zou; Cheng Li; Xiaojun Chen; Hangchao Gu; Zhiyang Zhou; Zuwei Yang; Yaoyao Tu; Ningxin Qin; Yiran Zhao; Yimei Wu; Yicong Meng; Guolian Ding; Xinmei Liu; Jianzhong Sheng; Chuanjin Yu; Hefeng Huang
Journal:  EBioMedicine       Date:  2020-10-21       Impact factor: 8.143

4.  Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer.

Authors:  Heidi Fettke; Edmond M Kwan; Maria M Docanto; Patricia Bukczynska; Nicole Ng; Lisa-Jane K Graham; Kate Mahon; Christine Hauser; Winston Tan; Xiao Hong Wang; Zhixin Zhao; Tiantian Zheng; Kemin Zhou; Pan Du; Jianjun Yu; Yong Huang; Shidong Jia; Manish Kohli; Lisa G Horvath; Arun A Azad
Journal:  Eur Urol       Date:  2020-05-30       Impact factor: 20.096

5.  Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer.

Authors:  Ying Z Mazzu; Joshua Armenia; Subhiksha Nandakumar; Goutam Chakraborty; Yuki Yoshikawa; Lina E Jehane; Gwo-Shu Mary Lee; Mohammad Atiq; Nabeela Khan; Nikolaus Schultz; Philip W Kantoff
Journal:  Mol Oncol       Date:  2020-05-31       Impact factor: 6.603

6.  Efficacy and Safety of Abiraterone Acetate and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.

Authors:  ZhenHeng Wei; ChuXin Chen; BoWen Li; YongYue Li; Hong Gu
Journal:  Front Oncol       Date:  2021-08-27       Impact factor: 6.244

7.  Positive epigenetic regulation loop between AR and NSUN2 promotes prostate cancer progression.

Authors:  Wenkai Zhu; Fangning Wan; Wenhao Xu; Zheng Liu; Junjie Wang; Hena Zhang; Shenglin Huang; Dingwei Ye
Journal:  Clin Transl Med       Date:  2022-09

8.  Plasma Cell-Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer.

Authors:  Edmond M Kwan; Chao Dai; Heidi Fettke; Christine Hauser; Maria M Docanto; Patricia Bukczynska; Nicole Ng; Siavash Foroughi; Lisa-Jane K Graham; Kate Mahon; Winston Tan; Xiaohong Wang; Zhixin Zhao; Tiantian Zheng; Kemin Zhou; Jianjun Yu; Pan Du; Lisa G Horvath; Shidong Jia; Manish Kohli; Arun A Azad
Journal:  JCO Precis Oncol       Date:  2021-04-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.